Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05288504 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
A Phase 2 study, sponsored by Avalo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT05288504 is a Phase 2 study that has completed, run by Avalo Therapeutics. The registered enrollment target is 91 participants.
The verdict
NCT05288504, a Phase 2 study, has completed, sponsored by Avalo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).
Interventions
- DRUG Placebo
- DRUG AVTX-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2023-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05288504
The ClinicalTrials.gov registry entry for NCT05288504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avalo Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05288504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05288504 about?
NCT05288504 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.". The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).
What is the current status of trial NCT05288504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2022-02-24. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT05288504?
The interventions under investigation include: Placebo (DRUG), AVTX-002 (DRUG).
Who is sponsoring clinical trial NCT05288504?
This trial is sponsored by Avalo Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.